Small Molecules

Search our small molecule opportunities against novel cancer targets and pathways. We have drug discovery, pre-clinical and clinical stage opportunities available for co-development and/or licensing.

First-in-class inhibitors of Atypical Protein Kinase C (aPKC)

Opportunity for a first-in-class oncology asset, through parallel preclinical disease positioning and toxicology/phase I plan approach.

Inhibitors of Cdc7

CRUK Commercial Partnerships is seeking a partner to progress our lead compounds to clinical investigation for development of Cdc7 inhibition-based cancer therapy.

First-in-Class IKK Alpha Selective Compounds

We are seeking a co-development or licensing partner to drive candidate selection and entry into formal pre-clinical studies.

Novel FAK-selective Inhibitors

Small Molecules - In Vivo Proof of Principle

Novel FLT3-FAK-VEGFR3 Triple Kinase Inhibitors

We are seeking prospective commercial partners with an interest in global therapeutic rights to the FLT3-FAK-VEGFR3 triple kinase inhibitor programme on an exclusive basis.

Cancer Research Technology

You are here

Small Molecules

Pages